American Society of Clinical Oncology

SHERPA: White

People

  1. Ostrovnaya
    Ostrovnaya
  2. Iyer
    Iyer
  3. Regazzi
    Regazzi
  4. Rosenberg
    Rosenberg
  5. Bajorin
    Bajorin
  6. Al-Ahmadie
    Al-Ahmadie
  7. Funt
    Funt
  8. Solit
    Solit
  9. Bochner
    Bochner
  10. Cha
    Cha

Groups

  1. Biostatistics Service (73)
  2. Epidemiology and Biostatistics (73)
  3. Department of Medicine (68)
  4. Solid Tumor Oncology Division (68)
  5. Genitourinary Oncology Service (62)
  6. GSK Faculty (41)
  7. Surgery (36)
  8. Department of Pathology and Laboratory Medicine (35)
  9. Urology (34)
  10. Weinberg Fellows (30)
Search Within
  1. "Irina Ostrovnaya"
Formats
  1. Meeting Abstract (58)
  2. Journal Article (15)
Groups
  1. Biostatistics Service (73)
  2. Epidemiology and Biostatistics (73)
  3. Department of Medicine (68)
  4. Solid Tumor Oncology Division (68)
  5. Genitourinary Oncology Service (62)
  6. GSK Faculty (41)

More Groups

People
  1. Irina Ostrovnaya (73)
  2. Dean Bajorin (48)
  3. Gopakumar Iyer (34)
  4. Ashley Regazzi (32)
  5. Jonathan Rosenberg (32)
  6. Hikmat Al-Ahmadie (28)

More People

Years
  1. 2024 (6)
  2. 2023 (5)
  3. 2022 (5)
  4. 2021 (2)
  5. 2020 (6)
  6. 2019 (5)

More Years

Publications
  1. Journal of Clinical Oncology (71)
  2. JCO Precision Oncology (2)

Results (73)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Bajorin, D. F.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO)
    Meeting Abstract

    Gupta, A.; Whiting, K.; Keegan, N. M.; Schmalz, J.; Al-Ahmadie, H. A.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Iyer, G.; Rosenberg, J. E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Natural history and genomic landscape of chemotherapy-resistant muscle-invasive bladder cancer
    Journal Article

    Lenis, A. T.; Whiting, K.; Ravichandran, V.; Tallman, J. E.; Alam, S. M.; Chu, C. E.; De Jesus Escano, M.; Bochner, E.; Katims, A.; Reisz, P. A.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Ancestry-adjusted genomic analysis to identify known and novel associations with single and multiple cancer phenotypes
    Meeting Abstract

    Joseph, V.; Ravichandran, V.; Ostrovnaya, I.; Liu, Y. L.; Tkachuk, K.; Khurram, A.; Kemel, Y.; Mandelker, D.; Bandlamudi, C.; Walsh, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Meeting Abstract

    Mohamadpour, M.; Sherman, E. J.; Kriplani, A.; Fetten, J. V.; Dunn, L.; Michel, L. S.; Hung, K. W.; Baxi, S. S.; McDonald, E.; Conybeare, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Novel genetic subtypes of urothelial carcinoma with differential outcomes on immune checkpoint blockade
    Journal Article

    Sarfaty, M.; Golkaram, M.; Funt, S. A.; Al-Ahmadie, H.; Kaplan, S.; Song, F.; Regazzi, A.; Makarov, V.; Kuo, F.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214
    Meeting Abstract

    Voss, M. H.; Shah, N. J.; Kalvin, H. L.; Lihm, J.; Li, H.; Kotecha, R. R.; Jarchum, I.; Vemula, S. V.; Gupta, S.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save